2025 MLS Seattle
Event Ended
This event has ended. Registration is no longer available.
Event Schedule
Event Overview
This accredited education activity delivers a comprehensive, practice-focused update on the use of systemic therapies in oncology, with emphasis on immunotherapy, targeted agents, and personalized treatment strategies. Designed to support clinical decision-making in the management of gastrointestinal, genitourinary, lung, and breast cancers, the lecture series will feature evidence-based presentations, expert panels, multidisciplinary tumor boards, and interactive, case-based discussions. Participants will explore real-world applications of novel agents such as HER2-directed therapies, antibody-drug conjugates, FGFR and PARP inhibitors, and targeted therapies for RET, BRAF, and KRAS mutations. Through collaborative dialogue and expert insight, learners will enhance their ability to integrate emerging clinical data and molecular diagnostics into personalized care plans, improve patient outcomes, and navigate ongoing therapeutic controversies in oncology practice.
Instructions for Credit
Thank you for attending this conference. Your feedback is valuable to us.
To receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.
Registered attendees can earn a maximum of 6.75 CME/ABIM MOC/CE credits. You will be able to select the amount of credits being claimed.
Physicians: If you would like to earn MOC credit please complete the Post-Test prior to submitting the evaluation. Once submitted, you will not be able to go back to complete the Post-Test. In order for MEC to report your MOC credit, your ABIM Diplomate ID number and date of birth (mm/dd/yyyy) MUST be included in your MyMedflix user profile. A completed evaluation and passing score of 70% on the post-test is required. You will have (3) attempts to pass the test.
Pharmacists: NABP e-profile number and date of birth (mm/dd/yyyy). Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Credits
- AMA PRA Category 1 Credit™6.75
- IPCE Credits6.75
- Nursing6.75
- Pharmacy6.75
Universal Activity Number(s)
Pharmacist: JA4008179-0000-25-014-L01-P
Event Details
- Duration
- 6.75 hours
- Start Date
- December 13th, 2025 7:15 AM (PST)Eastern: December 13th, 2025 10:15 AMCentral: December 13th, 2025 9:15 AMMountain: December 13th, 2025 8:15 AM
- End Date
- December 13th, 2025 4:40 PM (PST)Eastern: December 13th, 2025 7:40 PMCentral: December 13th, 2025 6:40 PMMountain: December 13th, 2025 5:40 PM
Objectives
t the conclusion of this activity, participants will be better able to: Apply emerging clinical data on novel systemic therapies including immunotherapies, antibody-drug conjugates, and PARP inhibitors to treatment strategies for patients with GI, GU, lung, and breast cancers. Interpret molecular and biomarker testing results (e.g., HER2, FGFR, RET, BRAF, KRAS) to guide therapeutic selection and personalize oncology care. Evaluate the safety profiles and mechanisms of action of newly approved agents and investigational treatments and integrate this knowledge into patient counseling and monitoring strategies. Assess the role of multidisciplinary collaboration in managing complex cancer cases through tumor board participation and interprofessional planning. Describe the design and goals of ongoing clinical trials, and identify patients who may be appropriate candidates for enrollment based on disease characteristics and therapeutic needs.
Target Audience
This activity is intended for medical oncologists, oncology pharmacists, oncology nurses, nurse practitioners (NPs), and clinical nurse specialists, physician associates/assistants (PAs), hematology/oncology fellows and residents and other healthcare professionals involved in the care of patients with cancer.
Faculty & Disclosure
Faculty
No Faculty or Disclosure
Disclosure
No Faculty or Disclosure
Accreditation
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 6.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
The Medical Educator Consortium designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”
Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)
Nursing
The Medical Educator Consortium designates this activity for 6.75 ANCC contact hours.
Pharmacist
This Knowledge-based activity has been approved for 6.75 contact hours (0.675 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-25-014-L01- P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
Physician Associate
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may claim a maximum of 6.75 Category 1 credits for completing this activity.